Brain Canada Brain Canada
FR Donate

Our directory of funded grants

6 result(s) found

Advancing biology based therapies for rhabdoid brain tumours

Project Overview

Rhabdoid brain tumours are the most common brain cancers in infants. Usually these aggressive tumours are treated with intense chemotherapy and radiation therapy, which can have serious side effects. Dr Annie Huang found that these brain tumours come in 2 forms, including one that can be cured using…

See researchers on this project
Principal Investigator:
  • Annie Huang, The Hospital For Sick Children

Deciphering eEF2K biological functions for therapeutic targeting of neural tumours

Project Overview

In childhood, medulloblastoma (a form of brain cancer) and neuroblastoma (a cancer that starts in the nerve cells) can be aggressive and hard to treat. Dr Poul Sorensen’s group is targeting what he believes is the Achilles heel of tumour cells: namely, how they adapt and survive under stress. He h…

See researchers on this project
Principal Investigator:
  • Poul Sorensen, University of British Columbia

Molecular heterogeneity drives the clinical behaviour of childhood medulloblastoma

Project Overview

Brain cancer is the most common type of solid cancer in children in Canada, and medulloblastoma is the most common malignant brain cancer of childhood.  Children diagnosed with medulloblastoma are often left with long-term effects from the intensive treatment. Dr. Taylor is studying how different m…

See researchers on this project
Principal Investigator:
  • Michael Taylor, The Hospital For Sick Children

Oncolytic rhabdovirus immunotherapy for brain cancer

Project Overview

Dr David Stojdl’s lab has custom‑built an oncolytic virus biotherapy specifically for the treatment of the devastating brain cancer, glioblastoma multiforme (GBM). Maraba‑LG kills brain cancer cells but leaves normal healthy tissue intact, and is one of the only oncolytic viruses in the world …

See researchers on this project
Principal Investigator:
  • David Stojdl, Children’s Hospital of Eastern Ontario (CHEO)

Synergistic combination of IAP antagonism and immunotherapy to treat brain cancers

Project Overview

Brain cancers can be exceptionally challenging to treat, and new therapies are needed. Cancer cells can resist treatment in part through proteins that protect cells from dying called IAPs. Dr Robert Korneluk has found that combining IAP-blocking drugs with immunotherapy can kill cancer cells very ef…

See researchers on this project
Principal Investigator:
  • Robert Korneluk, University of Ottawa/CHEO